Caldera Therapeutics Launches with $112.5M Funding for China-Licensed IBD Bispecific Antibody
Caldera Therapeutics, a Cambridge, MA-based biotech, launched on January 14, 2026, with $112.5 million in Series A funding (including A-1 extension).
Funding from Atlas Venture, LifeArc Ventures (LAV), venBio ($75M Series A), and Omega Funds (lead on $37.5M A-1) with Wellington Management and Janus Henderson.
Lead program CLD-423 is a first-in-class bispecific antibody targeting IL-23p19 and TL1A for inflammatory bowel disease (IBD).
CLD-423 licensed from China's Qyuns Therapeutics for $10M upfront, ~25% equity, and up to $545M in milestones.
First patients dosed in Phase 1 trial of CLD-423 in healthy volunteers.